Sera Prognostics (NASDAQ:SERA) Stock Price Up 11.5% – Should You Buy?

Sera Prognostics, Inc. (NASDAQ:SERA) shares traded up 11.5% during mid-day trading on Wednesday . The stock traded as high as $2.06 and last traded at $2.03. Approximately 24,334 shares traded hands during trading, a decline of 46% from the average daily volume of 45,286 shares. The stock had previously closed at $1.82.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Craig Hallum initiated coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 target price on the stock. Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Sera Prognostics Stock Up 11.5%

The business has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $2.41. The stock has a market capitalization of $79.49 million, a price-to-earnings ratio of -3.12 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. On average, analysts forecast that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Insider Activity

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the sale, the chief executive officer owned 871,999 shares of the company’s stock, valued at $1,813,757.92. This trade represents a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 27,755 shares of company stock valued at $57,840 over the last ninety days. 11.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sera Prognostics

Several hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC raised its stake in shares of Sera Prognostics by 8.9% in the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after acquiring an additional 7,643 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Sera Prognostics during the fourth quarter worth approximately $31,000. Arkadios Wealth Advisors bought a new stake in Sera Prognostics during the first quarter worth approximately $25,000. Citadel Advisors LLC grew its holdings in Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Finally, Lido Advisors LLC acquired a new position in Sera Prognostics during the third quarter valued at approximately $68,000. 54.64% of the stock is owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.